Five Years of EJCRIM

*2018 data is a projection based on actual data as at 31/07/18*
In 2017 the amount of submissions increased but their quality was not always up-to-par, therefore the rejection rate increased up to 51%.

2018* has already seen an improvement of the quality and by 31/07 as many as 51 articles have been already published.

*2018 data is a projection based on actual data as at 31/07/18
2017 Publication Data

The journal is receiving more submissions (+21%) and can afford to reject more (+23%) than in 2016.

Published articles have increased by 5%, less than the past year as the rejection rate increased (51%).

In 2017, frequency of publication has increased to 10 issues.

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issues</td>
<td>7</td>
<td>7</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Articles x Iss</td>
<td>6/7</td>
<td>8</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Accepted</td>
<td>51</td>
<td>67</td>
<td>71</td>
<td>+6%</td>
</tr>
<tr>
<td>Published</td>
<td>50</td>
<td>61</td>
<td>64</td>
<td>+5%</td>
</tr>
<tr>
<td>Submitted</td>
<td>83</td>
<td>120</td>
<td>145</td>
<td>+21%</td>
</tr>
</tbody>
</table>
Where do our articles come from?

- Portugal: 36%
- Spain: 8%
- UK: 7%
- USA: 6%
- Italy: 4%
- Ireland: 4%
- Latvia: 3%
- France: 3%
- Japan: 3%
- Netherlands: 3%
- Middle East: 6%
- North Africa: 3%
- Far East: 1%
- South Asia: 4%
- Europe: 7%
- America: 1%
- America: 4%
- North Africa: 1%
- Middle East: 6%
- Europe: 7%
## Processing time and performance

Average time from:

<table>
<thead>
<tr>
<th>Peer Review</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission to first decision</td>
<td>10 days</td>
</tr>
<tr>
<td><strong>Production</strong></td>
<td></td>
</tr>
<tr>
<td>Final decision to online publication</td>
<td>4.5 weeks</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
</tr>
<tr>
<td>From submission to publication</td>
<td>7 weeks</td>
</tr>
</tbody>
</table>

*production time includes copyediting, author proof approval and check out payment.
## Web Traffic 2017

<table>
<thead>
<tr>
<th>Country</th>
<th>Sessions</th>
<th>New Users</th>
<th>Pg/Session</th>
<th>Avg Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>32,824</td>
<td>23,456</td>
<td>3,17</td>
<td>00:02:50</td>
</tr>
<tr>
<td>USA</td>
<td>6,928</td>
<td>6,239</td>
<td>1,49</td>
<td>00:00:41</td>
</tr>
<tr>
<td>Italy</td>
<td>3,000</td>
<td>1,132</td>
<td>7,27</td>
<td>00:09:30</td>
</tr>
<tr>
<td>Portugal</td>
<td>2,532</td>
<td>1,345</td>
<td>4,49</td>
<td>00:03:48</td>
</tr>
<tr>
<td>UK</td>
<td>2,174</td>
<td>1,823</td>
<td>2,00</td>
<td>00:01:23</td>
</tr>
<tr>
<td>India</td>
<td>1,757</td>
<td>1,158</td>
<td>4,07</td>
<td>00:02:42</td>
</tr>
<tr>
<td>Canada</td>
<td>777</td>
<td>707</td>
<td>1,65</td>
<td>00:01:00</td>
</tr>
<tr>
<td>Spain</td>
<td>925</td>
<td>647</td>
<td>3,36</td>
<td>00:02:46</td>
</tr>
<tr>
<td>Australia</td>
<td>649</td>
<td>604</td>
<td>1,53</td>
<td>00:00:38</td>
</tr>
<tr>
<td>Germany</td>
<td>702</td>
<td>550</td>
<td>2,51</td>
<td>00:01:41</td>
</tr>
<tr>
<td>Japan</td>
<td>805</td>
<td>484</td>
<td>2,95</td>
<td>00:02:14</td>
</tr>
</tbody>
</table>

### 2016

<table>
<thead>
<tr>
<th></th>
<th>Session s</th>
<th>New Users</th>
<th>Pg/Sessi</th>
<th>Avg Dur.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>21,279</td>
<td>14,588</td>
<td>4,01</td>
<td>00:03:31</td>
</tr>
</tbody>
</table>

54%
Indexing

One of the focuses for 2017 was to get indexed in as many services as possible. We did our best…

And…
EJCRIM recently passed the scientific quality evaluation by PubMed Central.

We are now dealing with the technical aspects of the indexing and expect to be fully indexed by early 2019.

Published articles starting from 2016 are going to be included in PMC.
Citations

EJCRIM articles have been cited about 50 times, which is a +250% increase and step forward in comparison with 2016.

The most cited article is
von Wowern F, Brizzi M, Holst J. Reversal of the anticoagulation effects of dabigatran etexilate by idarucizumab in three patients needing urgent surgical intervention and one case of intravenous thrombolysis in ischaemic stroke. EJCRIM 2017;4.doi:10.12890/2017_000569 that has been cited 5 times in a year.

The Journal that cites us most is Reactions Weekly by Springer.
Improvements and upgrades

- Upgraded peer-review platform
- Graphic design upgrade
- New Editorial Board members

- Mikkel Brabrand (DK)
- Ettore Bartoli (IT)
- Eleni Boutati (GR)
- Tim Cooksley (UK)
- Dan Justo (IS)
- Pier Mannuccio Mannucci (IT)
- Alberto Marra (DE)
- Carla Araujo Pimentel (PT)
- Ramon Pujol (ES)
- Shirley Rigby (UK)
Social EJCRIM

EJCRIM needs to keep in touch with its audience – what’s a better occasion than a Conference?

2015-2017 Best Case Report Competition have been held in collaboration with EFIM Young Internists and SIMI.

At ECIM Meetings:
• Speed review
• Meet the Editor
• Best Case Report Competition

At SIMI Regional Meetings:
• Best Case Report Competition

Are you interested in a Case Competition for your Conference? Let’s talk!
Facebook is still a big part of the journal’s circulation life. Our audience seems to appreciate this outlet for newly published articles, forthcoming events and flash “useful news” and announcements. EJCRIM’s facebook page has to date 2,555 spontaneous likes.

The series “How to write a case report” has been shared as a weekly appointment through Facebook and had a fair reach. It is likely that it contributed to the article quality improvement.
What have I learnt?

- **Learning points**
  - Still don’t get it!

- **Literature searches**
  - Google and Uptodate

- **Over investigation**
  - Wisdom?

- **Association versus coincidence**
  - Lyme disease and sarcoidosis

- **Less is more**
  - From one lab value to the next

- **Rapid responders versus slow responders**
  - Read the reviewer’s comments